Immuno-oncology Simcere Zaiming Pharmaceutical patents new CBLB inhibitors April 4, 2023 Simcere Zaiming Pharmaceutical Co. Ltd. has disclosed tricyclic compounds acting as E3 ubiquitin-protein ligase CBL-B (CBLB) inhibitors...Read More
Cancer Simcere Zaiming Pharmaceutical reports development of USP1 inhibitors March 30, 2023 Ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors have been reported in a Simcere Zaiming Pharmaceutical Co. Ltd. patent as potentially useful for the treatment of cancer.Read More
